

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT POTENTIAL LICENSE AND COLLABORATION

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to inform the shareholders and potential investors of the Company that the Group is currently in negotiations with certain independent third parties regarding three potential transactions involving license and collaboration in relation to the development, manufacturing and commercialization of certain products of the Group, including epidermal growth factor receptor antibody drug conjugate (EGFR-ADC) and other pharmaceutical products developed under the Group’s technology platforms (the “**Potential Transactions**”).

The potential upfront payments, potential development milestone payments, potential commercialization milestone payments that may be payable to the Group under each of the Potential Transactions may amount to approximately US\$5 billion in aggregate. One of the Potential Transactions is at an advanced stage and is currently expected to be finalized in June 2025. Further announcement(s) will be published by the Company as and when necessary.

The terms and conditions of the Potential Transactions are yet to be finalized and no definitive agreement has been entered into by the Group regarding the Potential Transactions as of the date of this announcement. As such, the Potential Transactions may or may not proceed.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 30 May 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive Directors.